Correction to: The potential use of tideglusib as an adjuvant radio-therapeutic treatment for glioblastoma multiforme cancer stem-like cells

Jolie Bou-Gharios^{1,2} · Sahar Assi¹ · Hisham F. Bahmad^{1,3} · Hussein Kharroubi¹ · Tarek Araji¹ · Reda M. Chalhoub^{1,4} · Farah Ballout¹ · Hayat Harati² · Youssef Fares² · Wassim Abou-Kheir¹

Published online: 1 December 2020
© Maj Institute of Pharmacology Polish Academy of Sciences 2020

Correction to: Pharmacological Reports (2020)
<https://doi.org/10.1007/s43440-020-00180-5>

The original version of this article, published on November 2, 2020, contained a mistake.

The spelling of Youssef Fares' name was incorrect in this article. The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s43440-020-00180-5>.

✉ Youssef Fares
yfares@ul.edu.lb

✉ Wassim Abou-Kheir
wa12@aub.edu.lb

¹ Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Bliss Street, DTS Bldg, Room 116-B, Riad el Solh, PO Box 110236/41, Beirut 1107-2020, Lebanon

² Neuroscience Research Center, Lebanese University Faculty of Medicine, Beirut, Lebanon

³ Present Address: Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL, USA

⁴ Present Address: Medical Scientist Training Program, College of Medicine, Medical University of South Carolina, Charleston, SC, USA